Stocktoria
Celularity Inc CELU
Celularity Inc (CELU) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $26.6M at a -345.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CELU | Celularity Inc | 1/9 | — | — | -51% |
| CUE | Cue Biopharma, Inc. | 4/9 | — | — | — |
| TRDA | Entrada Therapeutics, Inc. | 2/9 | 4.24 | — | -87.9% |
| ALMS | ALUMIS INC. | 1/9 | -7.78 | — | — |
| NAMS | NewAmsterdam Pharma Co N.V. | 2/9 | 8.19 | — | -50.6% |
| FHTX | Foghorn Therapeutics Inc. | 1/9 | -10.28 | — | +36.8% |
| VSTM | Verastem, Inc. | 4/9 | -15.71 | — | +209.1% |
About Celularity Inc
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
FAQ
Is CELU financially healthy?
Celularity Inc's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does CELU pay a dividend?
No, Celularity Inc does not currently pay a dividend.
How profitable is CELU?
In FY2025, Celularity Inc had a net margin of -345.4%.
Is CELU a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Celularity Inc: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.